신경재활 기기 시장 보고서 : 제품 유형, 용도, 최종사용자, 지역별(2025-2033년)

The global neurorehabilitation devices market size reached USD 2.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.2% during 2025-2033.

Neurorehabilitation devices refer to the equipment used for examination of the brain and central nervous system (CNS). Some of the commonly used devices include neurorobotic systems, non-invasive brain stimulators, neuroprosthetics, brain-computer interfaces and wearable devices. These devices assist in the diagnosis and treatment of a disease, disorder or injury in the nervous system of the patient. They facilitate in re-learning motor skills and optimal recovery from neurological disorders, such as Parkinson's disease, and cardiovascular stroke. As a result, neurorehabilitation devices find extensive applications across various clinics, cognitive care and research institutes and healthcare centers.

Neurorehabilitation Devices Market Trends:

The increasing prevalence of neurological diseases, such as multiple sclerosis, Parkinson's disease and cerebral palsy, is one of the key factors driving the market growth. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the growth of the market. Neurorehabilitation devices aid in deploying diversified electric signals to multiple fibers of the spinal cord for the recovery of limb movements. Additionally, various technological advancements, such as the gamification of rehabilitation activities through virtual reality (VR), robotics and artificial intelligence (AI), that aid in promoting recovery are acting as other growth-inducing factors. In line with this, the utilization of novel multi-electrode stimulation for the treatment of spinal cord injuries is also contributing to the market growth. Other factors, including rising healthcare expenditure capacities of the masses, along with extensive research and development (R&D) activities, are anticipated to drive the market further.

Key Market Segmentation:

Breakup by Product Type:

• Neurorobotic Devices
• Wearable Devices
• Non-Invasive Stimulators
• Brain-Computer Interface

Breakup by Application:

• Stroke
• Multiple Sclerosis
• Parkinson's Disease
• Cerebral Palsy
• Others

Breakup by End User:

• Hospitals and Clinics
• Cognitive Care Centers
• Others

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Biometrics Ltd, Bioness Inc., Bionik Laboratories Corp, BioXtreme Ltd., Boston Scientific Corporation, Ectron Ltd, Ekso Bionics, Hocoma AG (DIH International Limited), Kinestica, Kinova Inc., Medtronic plc, Saebo Inc and Tyromotion GmbH.

Key Questions Answered in This Report

• 1.What was the size of the global neurorehabilitation devices market in 2024?
• 2.What is the expected growth rate of the global neurorehabilitation devices market during 2025-2033?
• 3.What are the key factors driving the global neurorehabilitation devices market?
• 4.What has been the impact of COVID-19 on the global neurorehabilitation devices market?
• 5.What is the breakup of the global neurorehabilitation devices market based on the product type?
• 6.What is the breakup of the global neurorehabilitation devices market based on the application?
• 7.What is the breakup of the global neurorehabilitation devices market based on the end user?
• 8.What are the key regions in the global neurorehabilitation devices market?
• 9.Who are the key players/companies in the global neurorehabilitation devices market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Neurorehabilitation Devices Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Neurorobotic Devices
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Wearable Devices
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Non-Invasive Stimulators
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Brain-Computer Interface
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Application

• 7.1 Stroke
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Multiple Sclerosis
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Parkinson's Disease
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Cerebral Palsy
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals and Clinics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Cognitive Care Centers
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Biometrics Ltd
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Bioness Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Bionik Laboratories Corp
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
  • 14.3.4 BioXtreme Ltd.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Boston Scientific Corporation
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Ectron Ltd
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Ekso Bionics
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Hocoma AG (DIH International Limited)
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Kinestica
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Kinova Inc.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 Medtronic plc
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis
  • 14.3.12 Saebo Inc
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
  • 14.3.13 Tyromotion GmbH
    • 14.3.13.1 Company Overview
    • 14.3.13.2 Product Portfolio
    • 14.3.13.3 Financials